Clinical and biological data before and at the end of 2-CdA treatment
| Clinical data responses . | No. of patients before treatment (%) . | No. of patients after treatment (%) . | P . |
|---|---|---|---|
| Mediators release symptoms | |||
| Fatigue | 53 (79) | 22 (33) | <.0001 |
| Flush | 34 (52) | 11 (17) | <.0001 |
| Pruritus | 33 (51) | 16 (25) | <.0001 |
| Diarrhea | 37 (55) | 9 (13) | <.0001 |
| Abdominal pain | 33 (49) | 12 (18) | <.0001 |
| Neuropsychiatric symptoms | 24 (37) | 13 (20) | .0009 |
| Headache/pain | 23 (34) | 15 (22) | .0046 |
| Nausea, vomiting | 22 (33) | 8 (12) | .0001 |
| Dyspnea | 14 (21) | 5 (7) | .007 |
| Anaphylaxis | 7 (10) | 0 (0) | .02 |
| Pollakiuria | 9 (14) | 5 (8) | .13 |
| Mast cell infiltration-related symptoms | |||
| Urticaria pigmentosa | 48 (73) | 10 (15) | <.0001 |
| Hepatomegaly | 34 (51) | 24 (36) (+1)* | .006 |
| Splenomegaly | 32 (48) | 24 (36) | .013 |
| Weight loss, fever, chills, night sweats (B-signs) | 25 (37) | 9 (13) | <.0001 |
| Lymphadenopathy | 18 (27) | 15 (22) (+2)* | .44 |
| Ascites | 15 (22) | 8 (12) | .023 |
| Biological parameters | |||
| Hemoglobin, g/dL | |||
| Hb <10 | 18 (27) | 13 (19) | .07 |
| Absolute eosinophil count, ×109/L | |||
| AEC >.5 | 14 (24) | 12 (21) | .5 |
| Platelet count, ×109/L | |||
| Platelet <100 | 14 (22) | 13 (19) | .24 |
| Liver parameters (total bilirubin, SAP, AST, ALT > UNL) | 9 (13) | 7 (10) (+1)* | .47 |
| Serum tryptase, ng/mL | |||
| Mean value | 172 | 97 | .01 |
| Median value | 79 | 53 |
| Clinical data responses . | No. of patients before treatment (%) . | No. of patients after treatment (%) . | P . |
|---|---|---|---|
| Mediators release symptoms | |||
| Fatigue | 53 (79) | 22 (33) | <.0001 |
| Flush | 34 (52) | 11 (17) | <.0001 |
| Pruritus | 33 (51) | 16 (25) | <.0001 |
| Diarrhea | 37 (55) | 9 (13) | <.0001 |
| Abdominal pain | 33 (49) | 12 (18) | <.0001 |
| Neuropsychiatric symptoms | 24 (37) | 13 (20) | .0009 |
| Headache/pain | 23 (34) | 15 (22) | .0046 |
| Nausea, vomiting | 22 (33) | 8 (12) | .0001 |
| Dyspnea | 14 (21) | 5 (7) | .007 |
| Anaphylaxis | 7 (10) | 0 (0) | .02 |
| Pollakiuria | 9 (14) | 5 (8) | .13 |
| Mast cell infiltration-related symptoms | |||
| Urticaria pigmentosa | 48 (73) | 10 (15) | <.0001 |
| Hepatomegaly | 34 (51) | 24 (36) (+1)* | .006 |
| Splenomegaly | 32 (48) | 24 (36) | .013 |
| Weight loss, fever, chills, night sweats (B-signs) | 25 (37) | 9 (13) | <.0001 |
| Lymphadenopathy | 18 (27) | 15 (22) (+2)* | .44 |
| Ascites | 15 (22) | 8 (12) | .023 |
| Biological parameters | |||
| Hemoglobin, g/dL | |||
| Hb <10 | 18 (27) | 13 (19) | .07 |
| Absolute eosinophil count, ×109/L | |||
| AEC >.5 | 14 (24) | 12 (21) | .5 |
| Platelet count, ×109/L | |||
| Platelet <100 | 14 (22) | 13 (19) | .24 |
| Liver parameters (total bilirubin, SAP, AST, ALT > UNL) | 9 (13) | 7 (10) (+1)* | .47 |
| Serum tryptase, ng/mL | |||
| Mean value | 172 | 97 | .01 |
| Median value | 79 | 53 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; SAP, serum alkaline phosphatase; UNL, upper normal limit.
(+n) corresponds to the appearance of clinical or biological sign in patient(s) without the biological sign at baseline.